Update on the Share Distribution of CANNORDIC Shares

New cut-off date allows additional time to finalize shareholder holdings and ensures accuracy in share distribution.

CS MEDICA A/S (CSMED) announces that the share distribution of CANNORDIC shares has been extended. The distribution, originally planned for shareholders registered as of today, November 22, 2024, will now be based on a new cut-off date. This adjustment is to ensure accuracy in the distribution process but also provides shareholders additional time to maximize their participation in the share distribution.
 

 Key Details:

• Reason for New Cut-Off Date: The extended timeline ensures the accurate delivery of CS MEDICA shares, as resolved during the Extraordinary General Meeting (EGM) on November 12, 2024. This step is critical for calculating the CANNORDIC share distribution accurately, ensuring a precise and seamless process.
• Distribution Ratio: The ratio remains unchanged, with one (1) free CANNORDIC share for every 200 CS MEDICA shares held.
• New Cut-Off Date: With the updated timeline, the new cut-off date for share distribution is estimated to be November 28, 2024. A final cut-off date will be confirmed and communicated soon. This extended timeline allows shareholders an opportunity to review and adjust their holdings if desired. 

This update reflects CS MEDICA’s dedication to ensuring a fair, transparent, and precise distribution process that benefits all shareholders. The company remains focused on completing the distribution efficiently and will share further updates as the process progresses.

Thank you for your understanding and continued support. For the latest updates, please visit cs-medica.com.

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/
 

CS MEDICA A/S, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally. The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.
 

CANNORDIC A/S, a subsidiary of CS MEDICA Group, is a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD. Our dedication to enhancing lives by integrating innovation, science, technology, and natural cannabis compounds positions it as a pioneer in the medical technology industry. The company ensures robust research, development, manufacturing, compliance, data insights, and commercialization processes.